134 related articles for article (PubMed ID: 26685653)
61. The timing of radium-223 therapy in castration-resistant prostate cancer.
Sartor O
Clin Adv Hematol Oncol; 2015 Sep; 13(9):570-2. PubMed ID: 26452186
[No Abstract] [Full Text] [Related]
62. Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
Buroni FE; Persico MG; Pasi F; Lodola L; Nano R; Aprile C
Anticancer Res; 2016 Nov; 36(11):5719-5730. PubMed ID: 27793893
[No Abstract] [Full Text] [Related]
63. Therapeutic effect of RA223 in the management of breast cancer bone metastases.
Costa RP; Tripoli V; Princiotta A; Murabito A; Licari M; Piazza D; Verderame F; Pinto A
Clin Ter; 2019; 170(1):e1-e3. PubMed ID: 30789190
[TBL] [Abstract][Full Text] [Related]
64. Extraction of
Großer OS; Wissel H; Wallbaum T; Genseke P; Kupitz D; Ricke J; Ruf J; Amthauer H
Nuklearmedizin; 2017 Jun; 56(3):69-72. PubMed ID: 28383088
[TBL] [Abstract][Full Text] [Related]
65. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
66. Highlights in Metastatic Prostate Cancer From the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.
Shore ND
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):17-9. PubMed ID: 27167847
[No Abstract] [Full Text] [Related]
67. Management of castration-resistant (advanced) prostate cancer (CRPC): rationale, progress and future directions.
Chopra S; Rashid P
Aust Fam Physician; 2015 May; 44(5):302-5. PubMed ID: 26042402
[TBL] [Abstract][Full Text] [Related]
68. Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.
Abou DS; Ulmert D; Doucet M; Hobbs RF; Riddle RC; Thorek DL
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26683407
[TBL] [Abstract][Full Text] [Related]
69. Radium-223: the newest option in metastatic castration-resistant prostate cancer.
Sartor O
Clin Adv Hematol Oncol; 2013 Dec; 11(12):801-3. PubMed ID: 24893286
[No Abstract] [Full Text] [Related]
70. Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases.
Zustovich F; Fabiani F
Crit Rev Oncol Hematol; 2014 Aug; 91(2):197-209. PubMed ID: 24503416
[TBL] [Abstract][Full Text] [Related]
71. NICE guidance on radium-223 dichloride for hormone-relapsed prostate cancer with bone metastases.
Umeweni N; Knight H; McVeigh G
Lancet Oncol; 2016 Mar; 17(3):275-6. PubMed ID: 26827242
[No Abstract] [Full Text] [Related]
72. Dovitinib reduces prostate cancer bone metastases.
Cancer Discov; 2014 Nov; 4(11):OF3. PubMed ID: 25367965
[No Abstract] [Full Text] [Related]
73. Abiraterone and increased survival in metastatic prostate cancer.
Parker C; Sartor O
N Engl J Med; 2011 Aug; 365(8):767. PubMed ID: 21864180
[No Abstract] [Full Text] [Related]
74. [Bone-targeted treatment in prostate cancer].
Géczi L; Sinkovics I
Magy Onkol; 2014 Sep; 58(3):199-203. PubMed ID: 25260084
[TBL] [Abstract][Full Text] [Related]
75. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
Dorff TB; Wilkins C; Hepgur M; Quinn DI
Clin Genitourin Cancer; 2014 Apr; 12(2):e55-8. PubMed ID: 24331572
[No Abstract] [Full Text] [Related]
76. 223Ra-dichloride response in a patient with Paget disease and bone metastases secondary to castration-resistant prostate cancer.
García Cañamaque L; Rioja Parada C; García De la Peña P
Tumori; 2017 Nov; 103(Suppl. 1):e53-e55. PubMed ID: 28525684
[TBL] [Abstract][Full Text] [Related]
77. Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer.
Takahashi M; Kusuhara Y; Mori H; Komori M; Kagawa J; Fukawa T; Yamamoto Y; Yamaguchi K; Fukumori T; Kanayama H
Clin Genitourin Cancer; 2015 Aug; 13(4):e337-e340. PubMed ID: 25770768
[No Abstract] [Full Text] [Related]
78. Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration.
Frantellizzi V; Pontico M; Pani A; Pani R; De Vincentis G
Curr Radiopharm; 2020; 13(2):159-163. PubMed ID: 31560295
[TBL] [Abstract][Full Text] [Related]
79. From the Guest Editor: The Spectrum of Treatment of Metastatic Prostate Cancer: Present and Future.
Petrylak DP
Cancer J; 2016; 22(5):321. PubMed ID: 27749323
[No Abstract] [Full Text] [Related]
80. Hungry bone syndrome secondary to prostate cancer successfully treated with radium therapy.
Garla VV; Salim S; Kovvuru KR; Subauste A
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 29982185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
